Core C: Virology will support Research Projects I, II and III and Cores B and D through the provision of specific reagents, antiviral and other anti-infective evaluations, and efficacy data for the pyrimidinediones, ISIS 5320 oligonucleotide, and NCp7 viral inactivating agents alone and in combination products. Core C will accomplish these goals by implementation of the following objectives: Objective 1: Primary Antiviral Efficacy and Toxicity Testing: The antiviral efficacy and toxicity data will utilize whole virus replication assays and specific cellular and biochemical assays to measure the antiviral effects of the active microbicide and formulated product based on their defined mechanisms of action. Toxicity evaluations will be performed in parallel for each antiviral measurement. Objective 2: Evaluation of the Activity of Combination Microbicide Products:
The aim of this objective is to utilize standard in vitro microbicide efficacy assays to evaluate, quantify and prioritize combinations of microbicide products to be developed as long-lasting microbicides for evaluation in ex vivo cervical explant models as well as for further development as gel and ring products. Objective 3: Evaluation of the Effects of Vaginal and Seminal Fluids on Viral Infectivity and Microbicide Efficacy and Toxicity: We will perform in vitro efficacy and toxicity evaluations using seminal plasma and vaginal fluid additives to each of the antiviral assays performed and to further define the biological properties of these fluids on viral infectivity, microbicide action, and cellular toxicity.Objective 4: Development of Microbicide-Resistant Virus Strains and Evaluation of the Ability of the Microbicides to Inhibit the Transmission of Wild Type and Resistant Virus: We will select for viruses that are resistant to each of the microbicides alone and in combination with one another and evaluate the ability of the microbicides to totally suppress the transmission of wild type and resistant viruses.Objective 5: Toxicity Evaluation of Microbicide Products and Formulated Materials: Cell-based in vitro toxicology testing will be performed utilizing cell lines, relevant Lactobacilli species, and ex vivo tissues. Objective 6: Preclinical Development of Microbicide Products Alone and In Combination: Lead microbicide products defined by the studies will be assessed for their antiviral potential consistent with their advancement to clinical testing.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AI077289-05
Application #
8380876
Study Section
Special Emphasis Panel (ZAI1-CCH-A)
Project Start
Project End
2014-05-31
Budget Start
2012-06-01
Budget End
2013-05-31
Support Year
5
Fiscal Year
2012
Total Cost
$114,796
Indirect Cost
$7,575
Name
Imquest Biosciences
Department
Type
DUNS #
146051664
City
Frederick
State
MD
Country
United States
Zip Code
21704
Morrow Guthrie, Kate; Vargas, Sara; Shaw, Julia G et al. (2015) The Promise of Intravaginal Rings for Prevention: User Perceptions of Biomechanical Properties and Implications for Prevention Product Development. PLoS One 10:e0145642
Rosen, Rochelle K; van den Berg, Jacob J; Vargas, Sara E et al. (2015) Meaning-making matters in product design: users' sensory perceptions and experience evaluations of long-acting vaginal gels and intravaginal rings. Contraception 92:596-601
Ugaonkar, Shweta R; Clark, Justin T; English, Lexie B et al. (2015) An Intravaginal Ring for the Simultaneous Delivery of an HIV-1 Maturation Inhibitor and Reverse-Transcriptase Inhibitor for Prophylaxis of HIV Transmission. J Pharm Sci 104:3426-39
Katz, David F; Yuan, Andrew; Gao, Yajing (2015) Vaginal drug distribution modeling. Adv Drug Deliv Rev 92:2-13
Gao, Y; Yuan, A; Chuchuen, O et al. (2015) Vaginal deployment and tenofovir delivery by microbicide gels. Drug Deliv Transl Res 5:279-94
van den Berg, Jacob J; Rosen, Rochelle K; Bregman, Dana E et al. (2014) ""Set it and forget it"": women's perceptions and opinions of long-acting topical vaginal gels. AIDS Behav 18:862-70
Tolley, Elizabeth E; Morrow, Kathleen M; Owen, Derek H (2013) Designing a multipurpose technology for acceptability and adherence. Antiviral Res 100 Suppl:S54-9
Rastogi, Rachna; Teller, Ryan S; Mesquita, Pedro M M et al. (2013) Osmotic pump tablets for delivery of antiretrovirals to the vaginal mucosa. Antiviral Res 100:255-8
Drake, Tyler K; Shah, Tejen; Peters, Jennifer J et al. (2013) Measuring dilution of microbicide gels with optical imaging. PLoS One 8:e82213
Dezzutti, Charlene S; Shetler, Cory; Mahalingam, Alamelu et al. (2012) Safety and efficacy of tenofovir/IQP-0528 combination gels - a dual compartment microbicide for HIV-1 prevention. Antiviral Res 96:221-5

Showing the most recent 10 out of 23 publications